Glaucoma Patents (Class 514/913)
  • Patent number: 8993636
    Abstract: Ophthalmic, otic and nasal compositions containing a new class of antibiotics (e.g., moxifloxacin) are disclosed. The compositions preferably also contain one or more anti-inflammatory agents. The compositions may be utilized to treat ophthalmic, otic and nasal conditions by topically applying the compositions to the affected tissues.
    Type: Grant
    Filed: October 25, 2013
    Date of Patent: March 31, 2015
    Assignee: Alcon Pharamceuticals, Ltd.
    Inventors: Gerald Cagle, Robert L. Abshire, David W. Stroman, John M. Yanni
  • Patent number: 8969415
    Abstract: Biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 10 days and one year or longer.
    Type: Grant
    Filed: December 1, 2006
    Date of Patent: March 3, 2015
    Assignee: Allergan, Inc.
    Inventors: Michael R. Robinson, Wendy M. Blanda, Patrick M. Hughes, Guadalupe Ruiz, Werhner C. Orilla, Scott M. Whitcup, Devin F. Welty, Joan-En Lin, Lon T. Spada
  • Patent number: 8906907
    Abstract: New compositions for and methods of treating ocular hypertension provide for effective treatment of ocular hypertension often using reduced concentrations of active components. Such compositions include a timolol component and a hypotensive lipid component. The present compositions and methods are relatively straightforward, can be easily produced, for example, using conventional manufacturing techniques, and can be easily and conveniently practiced, for example, using application or administration techniques or methodologies which are substantially similar to those employed with prior compositions used to treat ocular hypertension.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: December 9, 2014
    Assignee: Allergan, Inc.
    Inventors: June Chen, David F. Woodward, Alexander B. Kharlamb
  • Patent number: 8853257
    Abstract: The present invention provides methods and pharmaceutical compositions for treating ocular disorders associated with elevated intraocular pressure, such as glaucoma, by administering anti-epileptic or anti-convulsant compounds of the succinimide family, in particular compounds of formula I and/or II as defined herein.
    Type: Grant
    Filed: September 6, 2011
    Date of Patent: October 7, 2014
    Inventor: Mordechai Sharir
  • Patent number: 8709515
    Abstract: The method comprises steps of: providing a nutraceutical including, in combination, 1.13 to 3 mg lutein and 18.8 to 51.2 mg omega fatty acids and 1.9 to 5.2 mg grape seed extract and 1.9 to 5.2 mg alpha lipoic acid; determining the weight of each dose of the components in the combination based upon an amount per kg body weight of the animal patients; and administering 1 dose of nutraceutical per day to animals suffering from ocular health issues including any degenerative retinal disease and diabetic cataracts and prior to and following cataract surgery for the diminishment and prevention of secondary cataracts.
    Type: Grant
    Filed: March 23, 2012
    Date of Patent: April 29, 2014
    Inventors: Carmen C. H. Colitz, Terri L. McCalla, Debra A. Smith
  • Patent number: 8686001
    Abstract: The invention relates to an ophthalmic medicament for treating glaucoma which comprises a clathrate compound prepared by dissolving cilostazol or a salt thereof in a cyclodextrin.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: April 1, 2014
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Norio Okamoto, Yoshimasa Ito, Yoshimi Kawakami, Takuji Kurimoto, Noriaki Nagai, Tatsuya Yamashita
  • Patent number: 8673973
    Abstract: Provided is a method for treating ocular hypertension and glaucoma with reduced side effects such as keratoconjunctive disorders and macular edema, which comprises administering an ophthalmic composition comprising latanoprost as an active ingredient thereof to a subject in need of said treatment, wherein the ophthalmic composition contains substantially no benzalkonium chloride.
    Type: Grant
    Filed: May 23, 2006
    Date of Patent: March 18, 2014
    Assignee: Sucampo AG (USA) Inc.
    Inventor: Ryuji Ueno
  • Patent number: 8669253
    Abstract: Inhibition of geranylgeranylation of Rho GTPases and heterotrimeric G-proteins in the aqueous outflow pathway increases aqueous humor outflow, possibly through the tissue relaxation, and through altered cell adhesive interactions and actin cytoskeletal organization in cells of the outflow pathway. In addition, such inhibition is useful for treating age-related macular degeneration. The GGTase-I enzyme is a molecular target for lowering increased ocular pressure in glaucoma patients.
    Type: Grant
    Filed: March 12, 2007
    Date of Patent: March 11, 2014
    Assignee: Duke University
    Inventors: Vasantha P. Rao, Patrick J. Casey, Peifeng Deng, Yuri K. Peterson
  • Patent number: 8658624
    Abstract: The present invention relates to pharmacology, medicine, opthalmology, and, in particular, concerns a class of chemical compounds of structure (I) and also their solvates, isomers or prodrugs applicable when incorporated into pharmaceutical compositions also containing pharmaceutically acceptable carrier which can be useful for prophylaxis and treatment of different eye pathologies such as cataract and macular dystrophy.
    Type: Grant
    Filed: October 20, 2006
    Date of Patent: February 25, 2014
    Assignee: Mitotech SA
    Inventors: Vladimir P. Skulachev, Maxim V. Skulachev
  • Patent number: 8653123
    Abstract: The present invention relates to method of treating retinal diseases in a subject in need of such treatment, which comprises administering a therapeutically effective amount of a composition comprising a ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl) -2-methylphenyl]methanol, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.
    Type: Grant
    Filed: September 15, 2011
    Date of Patent: February 18, 2014
    Assignee: Allergan, Inc.
    Inventors: Mohammad I. Dibas, Daniel W. Gil, Ken Chow, Liming Wang, Michael E. Garst, John E. Donello
  • Patent number: 8648169
    Abstract: The present invention relates to methods of treating or preventing retinal ganglion cell (RGC) death and/or glaucoma using modulators of neurotrophic receptors that comprise ?-turn peptidomimetic cyclic compounds or derivatives thereof. The neurotrophic receptor modulators can be used alone, in combination and/or in conjunction with one or more other compounds, molecules or drugs that treat or prevent ocular hypertension, RGC death and/or glaucoma.
    Type: Grant
    Filed: December 5, 2007
    Date of Patent: February 11, 2014
    Assignee: The Royal Institution for the Advancement of Learning/McGill University
    Inventor: H. Uri Saragovi
  • Patent number: 8637054
    Abstract: This invention concerns an ophthalmic solution including: at least one prostaglandin; a solubilizing agent; a gelling agent of the carbomer type; a carbomer polymerization-inhibiting agent; a co-gelling/co-solubilizing agent.
    Type: Grant
    Filed: August 27, 2012
    Date of Patent: January 28, 2014
    Assignee: Laboratoires Thea
    Inventor: Fabrice Mercier
  • Patent number: 8629140
    Abstract: New compositions for and methods of treating ocular hypertension provide for effective treatment of ocular hypertension often using reduced concentrations of active components. Such compositions include a timolol component and a hypotensive lipid component. The present compositions and methods are relatively straightforward, can be easily produced, for example, using conventional manufacturing techniques, and can be easily and conveniently practiced, for example, using application or administration techniques or methodologies which are substantially similar to those employed with prior compositions used to treat ocular hypertension.
    Type: Grant
    Filed: May 22, 2002
    Date of Patent: January 14, 2014
    Assignee: Allergan, Inc.
    Inventors: June Chen, David F. Woodward, Alexander B. Kharlamb
  • Patent number: 8629161
    Abstract: There is provided a preventive for glaucoma or a preventive or a remedy for ocular hypertension, with a potent ocular hypotensive effect and prolonged duration thereof. A preventive or a remedy for glaucoma comprising a Rho kinase inhibitor and an ?1 blocker in combination.
    Type: Grant
    Filed: June 20, 2006
    Date of Patent: January 14, 2014
    Assignee: Kowa Co., Ltd.
    Inventors: Ken Mizuno, Jiro Matsumoto
  • Patent number: 8618093
    Abstract: New compositions for and methods of treating ocular hypertension provide for effective treatment of ocular hypertension often using reduced concentrations of active components. Such compositions include a timolol component and a hypotensive lipid component. The present compositions and methods are relatively straightforward, can be easily produced, for example, using conventional manufacturing techniques, and can be easily and conveniently practiced, for example, using application or administration techniques or methodologies which are substantially similar to those employed with prior compositions used to treat ocular hypertension.
    Type: Grant
    Filed: March 20, 2009
    Date of Patent: December 31, 2013
    Assignee: Allergan, Inc.
    Inventors: June Chen, David F. Woodward, Alexander B. Kharlamb
  • Patent number: 8609658
    Abstract: The invention provides well defined N,N-dialkylalkenyl ester compounds for treating glaucoma or ocular hypertension. The esters of the invention are particularly advantageous due to their stability in aqueous solutions.
    Type: Grant
    Filed: July 25, 2012
    Date of Patent: December 17, 2013
    Assignee: Allergan, Inc.
    Inventors: Robert M. Burk, David W. Old
  • Patent number: 8580789
    Abstract: Provided herein are methods of protecting all or a portion of the optic nerve fiber layer within the optic nerve/lamina cribrosa (ONLC) complex in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of an agent that results in crosslinking of collagen in the indiviudal's peripapillary sclera, thereby stiffening the individual's peripapillary sclera and protecting all or a portion of the optic nerve fiber layer within the ONLC of the individual. In a particular embodiment, the invention is directed to methods of treating glaucoma in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of an agent that results in crosslinking of collagen in the indiviudal's peripapillary sclera, thereby stiffening the individual's peripapillary sclera and treating the glaucoma in the individual.
    Type: Grant
    Filed: April 2, 2008
    Date of Patent: November 12, 2013
    Assignees: The Cleveland Clinic Foundation
    Inventors: Ronald R. Krueger, William J. Dupps, Stephen Trokel, Ivey Thornton
  • Patent number: 8541413
    Abstract: This invention provides for biocompatible, biodegradable eye drop pharmaceutical formulations useful for the treatment of ocular indications. In particular, tocopherols and their esters of low water solubility, notably ?-tocopheryl acetate, are exceptional vehicles for biocompatible, nonirritating topical eye drop formulations that provide sustained release of active agents.
    Type: Grant
    Filed: September 24, 2008
    Date of Patent: September 24, 2013
    Assignee: Ramscor, Inc.
    Inventors: Vernon G. Wong, Louis L. Wood
  • Patent number: 8529927
    Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants can be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, including reduction of an elevated intraocular pressure.
    Type: Grant
    Filed: March 31, 2006
    Date of Patent: September 10, 2013
    Assignee: Allergan, Inc.
    Inventors: James N. Chang, Lon T. Spada, Wendy M. Blanda, Werhner C. Orilla, James A. Burke, Patrick M. Hughes
  • Patent number: 8383650
    Abstract: The present invention relates to a compound of the formula I wherein R1, R2, R3, R4 and R5 are as defined in the specification, for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations a compound of that class; a method of treatment comprising administering a compound of that class and a method for its manufacture.
    Type: Grant
    Filed: June 25, 2008
    Date of Patent: February 26, 2013
    Assignee: Novartis AG
    Inventors: Fumiaki Yokokawa, Takeru Ehara, Shimpei Kawakami, Osamu Irie, Masaki Suzuki, Yuko Hitomi, Atsushi Toyao
  • Patent number: 8324271
    Abstract: An eye drop composition in which the degradation of isopropyl unoprostone in an eye drop is prevented by adding trometamol to the eye drop containing isopropyl unoprostone.
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: December 4, 2012
    Assignee: R-Tech Ueno, Ltd.
    Inventors: Hiroyuki Asada, Akio Kimura
  • Patent number: 8211880
    Abstract: Triamcinolone acetonide suspension compositions are disclosed. The suspension compositions have a relatively low viscosity and are easy to extrude through a 27- or 30-guage needle but are highly flocculated and easily redispersed. The compositions are particularly suitable for intravitreal injection.
    Type: Grant
    Filed: January 17, 2012
    Date of Patent: July 3, 2012
    Assignee: Alcon Research, Ltd.
    Inventors: Bhagwati P. Kabra, Ruma Sarkar
  • Patent number: 8173668
    Abstract: The invention provides methods for treating and/or preventing ocular disorders associated with increased intraocular pressure comprising administering a non-peptide bradykinin agonist to a patient in need thereof.
    Type: Grant
    Filed: June 5, 2008
    Date of Patent: May 8, 2012
    Assignee: Alcon Research, Ltd.
    Inventor: Najam A. Sharif
  • Patent number: 8053407
    Abstract: The present invention relates to a method of treating a neurological condition in a mammal by administering at least one hematopoietic growth factor.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: November 8, 2011
    Assignee: Sygnis Bioscience GmbH & Co. KG
    Inventors: Wolf-Ruediger Schaebitz, Armin Schneider, Carola Krueger, Clemens Sommer, Stefan Schwab, Rainer Kollmar, Martin Maurer, Daniela Weber, Nikolaus Gassler
  • Patent number: 8030349
    Abstract: The present invention provides a method for preventing the degradation of a thermally unstable medicament in an eye drop containing the medicament thereby to stabilize the eye drop. By adding an organic amine to an eye drop containing a thermally unstable medicament, the degradation of the medicament in the eye drop can be effectively prevented, and therefore the eye drop can be stably stored.
    Type: Grant
    Filed: August 2, 2006
    Date of Patent: October 4, 2011
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Hiroyuki Asada, Akio Kimura
  • Patent number: 8017655
    Abstract: The present invention provides cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compounds, which may be substituted in the 1-position with amino, amido, ether or ester groups, e.g., a 1-OH cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compound. The cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compounds of the present invention are potent ocular hypotensives, and are particularly suitable for the management of glaucoma. Moreover, the cyclopentane heptanoic, 2-(cycloalkyl or arylalkyl) compounds of this invention are smooth muscle relaxants with broad application in systemic hypertensive and pulmonary diseases; smooth muscle relaxants with application in gastrointestinal disease, reproduction, fertility, incontinence, shock, etc.
    Type: Grant
    Filed: December 19, 2008
    Date of Patent: September 13, 2011
    Assignee: Allergan, Inc.
    Inventors: David F. Woodward, Steven W. Andrews, Robert M. Burk, Michael E. Garst
  • Patent number: 7972612
    Abstract: A subject of the present invention is to find utility of a combination of a Rho kinase inhibitor having a novel action and a ?-blocker as a therapeutic agent for glaucoma. Actions of reducing intraocular pressure are complemented and/or enhanced each other by combining the Rho kinase inhibitor with the ?-blocker. For the administration mode, each drug can be administered in combination or in mixture.
    Type: Grant
    Filed: November 17, 2003
    Date of Patent: July 5, 2011
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Masakazu Hatano, Tadashi Nakajima, Takeshi Matsugi, Hideaki Hara
  • Patent number: 7914803
    Abstract: Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of three polymers that have a synergistic effect on viscosity.
    Type: Grant
    Filed: February 9, 2007
    Date of Patent: March 29, 2011
    Assignee: Alcon, Inc.
    Inventors: Masood A. Chowhan, Huagang Chen
  • Patent number: 7897594
    Abstract: An alkyl ether derivative represented by the following general formula [1] or its salt: wherein R1 and R2 represent each a substituent such as hydrogen, halogeno or alkyl; R3 represents alkylamino, amino or hydroxyl; the ring A represents a 5- or 6-membered aromatic heterocycle or a benzene ring; m and n are each an integer of from 1 to 6; and p is an integer of from 1 to 3; shows an effect of protecting retinal nerve cells and, therefore, is useful as a preventive and/or a remedy for retinal nerve diseases such as glaucoma, diabetic retinopathy, retinal artery obstruction, retinal venous obstruction, macular degeneration and retinopathy of prematurity.
    Type: Grant
    Filed: August 17, 2009
    Date of Patent: March 1, 2011
    Assignee: Toyama Chemical Co., Ltd.
    Inventors: Tatsuo Kimura, Noboru Iwakami, Akihito Saitoh
  • Patent number: 7867999
    Abstract: Methods for using hydroxyamino- and amino-substituted pyridine analogs are disclosed herein to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an effective amount of hydroxyamino- and amino-substituted pyridine analogs, are disclosed herein.
    Type: Grant
    Filed: December 19, 2006
    Date of Patent: January 11, 2011
    Assignee: Alcon Research, Ltd.
    Inventors: Hwang-Hsing Chen, Najam A. Sharif, Mark R. Hellberg
  • Patent number: 7754768
    Abstract: Methods and compositions for the treatment of pain and intraocular pressure. Particularly disclosed are new compositions for the treatment of chronic pain, glaucoma and methods for their use.
    Type: Grant
    Filed: February 1, 2008
    Date of Patent: July 13, 2010
    Assignee: Allergan, Inc.
    Inventors: Ken Chow, Daniel W. Gil, Wenkui Ken Fang, Michael E. Garst, Larry A. Wheeler
  • Patent number: 7625864
    Abstract: The present invention provides a method for treating and/or preventing damage to a retina or optic nerve in a subject comprising administering to the subject a therapeutically effective amount of oncomodulin. Preferably, the subject is a mammal, most preferably, a human. In preferred embodiments, the oncomodulin may be used in combination with mannose, a mannose derivative and/or inosine.
    Type: Grant
    Filed: June 30, 2008
    Date of Patent: December 1, 2009
    Assignee: Children's Medical Center Corporation
    Inventors: Larry I. Benowitz, Yuqin Yin
  • Patent number: 7625927
    Abstract: Described are methods for the treatment of ocular hypertension or glaucoma comprising administering a pharmaceutically effective amount of one or more compounds that inhibit the enzyme EgLN-3. Certain embodiments of the invention combine the use of EgLN-3 with other glaucoma treatment agents. The compounds of the invention may be formulated in compositions comprising pharmaceutically acceptable carriers.
    Type: Grant
    Filed: February 27, 2007
    Date of Patent: December 1, 2009
    Assignee: Alcon Research, Ltd.
    Inventors: Peter G. Klimko, Iok-Hou Pang
  • Patent number: 7612082
    Abstract: Disclosed herein are methods and compositions related to compound 1 or compound 2 or pharmaceutically acceptable salts, or prodrugs thereof, which are antagonists of a prostaglandin EP4 receptor, or are prostaglandin EP4 antagonists.
    Type: Grant
    Filed: October 28, 2004
    Date of Patent: November 3, 2009
    Assignee: Allergan, Inc.
    Inventors: Larry A. Wheeler, Michael E. Garst, Yanbin Liang, David F. Woodward, Achim H.-P. Krauss, Robert M. Burk, Yariv Donde, Mark Holoboski, David W. Old, June Chen
  • Patent number: 7479481
    Abstract: Compositions and methods for treating ocular diseases and disorders are provided. The composition can contain at least one lantibiotic, which can be administered topically by injection, systemically, or by other appropriate means. The methods provided include the administration of a therapeutically effective amount of a formulation containing at least one lantibiotic to the appropriate section of the eye.
    Type: Grant
    Filed: May 6, 2005
    Date of Patent: January 20, 2009
    Assignee: Molichem Medicines, Inc.
    Inventor: Luis Molina
  • Patent number: 7329411
    Abstract: Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of three polymers that have a synergistic effect on viscosity.
    Type: Grant
    Filed: June 4, 2007
    Date of Patent: February 12, 2008
    Assignee: Alcon, Inc.
    Inventors: Masood A. Chowhan, Huagang Chen
  • Patent number: 7307096
    Abstract: A pharmaceutical composition for the prophylaxis or treatment of glaucoma which comprises an angiotensin II antagonist and at least one compound selected from an adrenaline receptor blocker, a prostaglandin and a carbonic anhydrase inhibitor; and a method for the prophylaxis or treatment of glaucoma by administering the composition to a patient.
    Type: Grant
    Filed: May 16, 2002
    Date of Patent: December 11, 2007
    Assignee: Sankyo Company, Limited
    Inventor: Tomihisa Yokoyama
  • Patent number: 7244440
    Abstract: Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of three polymers that have a synergistic effect on viscosity.
    Type: Grant
    Filed: June 8, 2004
    Date of Patent: July 17, 2007
    Assignee: Alcon, Inc.
    Inventors: Masood A. Chowhan, Huagang Chen
  • Patent number: 7220780
    Abstract: The present invention relates to pharmaceutical compositions and methods for treating a retinal disorder or glaucoma using NAALADase inhibitors.
    Type: Grant
    Filed: May 30, 2001
    Date of Patent: May 22, 2007
    Assignee: Guilford Pharmaceuticals Inc.
    Inventors: Barbara S. Slusher, Krystyna Wozniak
  • Patent number: 7129257
    Abstract: Pyrazolo[3,4-e]benzoxazoles and analogues thereof for lowering intraocular pressure and treating glaucoma are disclosed.
    Type: Grant
    Filed: December 15, 2004
    Date of Patent: October 31, 2006
    Assignee: Alcon, Inc.
    Inventors: Anura P. Dantanarayana, Jesse A. May
  • Patent number: 7084128
    Abstract: The present invention is directed to a method of reducing intraocular pressure. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a purinerginic receptor ligand, which is a mononucleoside polyphosphate or dinucleoside polyphosphate defined by general Formula I. The method of the present invention is useful in the treatment or prevention of ocular hypertension, such as glaucoma, including primary and secondary glaucoma. The method can be used alone to reduce intraocular pressure. The method can also be used in conjunction with other therapeutic agents or adjunctive therapy commonly used to treat glaucoma to enhance the therapeutic effect of reducing the intraocular pressure.
    Type: Grant
    Filed: January 15, 2003
    Date of Patent: August 1, 2006
    Assignee: Inspire Pharmaceuticals, Inc.
    Inventors: Benjamin R. Yerxa, Robert Plourde, Jr., Edward G. Brown, Ward M. Peterson
  • Patent number: 7005446
    Abstract: Compositions comprising AP-1 activators and methods of use for treating glaucoma and ocular hypertension are disclosed.
    Type: Grant
    Filed: April 7, 2000
    Date of Patent: February 28, 2006
    Assignee: Alcon Manufacturing, Ltd.
    Inventors: Debra L. Shade, Iok-Hou Pang, Abbot F. Clark
  • Patent number: 6960300
    Abstract: Aqueous solutions of diterpenes such as Forskolin, its congeners, analogs and derivatives, up to approximately 6% concentration, are prepared using suitably substituted cyclodextrin as a solubilizing agents. In the absence of cyclodextrin, some diterpenes such as Forskolin are soluble in water only to concentrations of about 0.001%. Such aqueous solutions find applications in topical and systemic use, as pharmaceutical, cosmeceutical, nutraceutical preparations containing diterpenes such as Forskolin and congeners.
    Type: Grant
    Filed: September 8, 2003
    Date of Patent: November 1, 2005
    Assignee: Sami Labs Limited
    Inventors: Muhammed Majeed, Arvind Kumar, Kalyanam Nagabhushanam, Subbalakshmi Prakash
  • Patent number: 6956057
    Abstract: The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound which is a EP4 agonist.
    Type: Grant
    Filed: September 26, 2003
    Date of Patent: October 18, 2005
    Assignee: Allergan, Inc.
    Inventors: David F. Woodward, Achim H. Krauss, Robert M. Burk, Mark Holoboski, Mari F. Posner
  • Patent number: 6927233
    Abstract: Compositions and methods for controlling intraocular pressure and treating glaucoma using 1-(2-aminopropyl)-indazol-6-ol are disclosed.
    Type: Grant
    Filed: November 14, 2000
    Date of Patent: August 9, 2005
    Assignees: Alcon, Inc., Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Jesse A. May, Anura P. Dantanarayana
  • Patent number: 6855690
    Abstract: The present invention provides a method for treating and/or preventing damage to a retina or optic nerve in a subject comprising administering to the subject a therapeutically effective amount of oncomodulin. Preferably, the subject is a mammal, most preferably, a human. In preferred embodiments, the oncomodulin may be used in combination with mannose, a mannose derivative and/or inosine.
    Type: Grant
    Filed: November 14, 2002
    Date of Patent: February 15, 2005
    Assignee: Children's Medical Center Corporation
    Inventor: Larry I. Benowitz
  • Patent number: 6770675
    Abstract: An improved ophthalmic composition, including docosanoid active agents, which is especially useful in lowering intraocular pressure associated with glaucoma. Improvements in IOP reduction efficacy, preservative efficacy and reduced additive concentrations are achieved by utilizing the disclosed compositions which include a docosanoid active agent (e.g., isopropyl unoprostone), in conjunction with selected non-ionic surfactants, preservatives, and non-ionic tonicity adjusting agents.
    Type: Grant
    Filed: March 19, 2001
    Date of Patent: August 3, 2004
    Assignee: Novartis AG
    Inventors: Kenneth Warren Reed, Shau Fong Yen, Mary Sou, Regina Flinn Peacock
  • Patent number: 6750196
    Abstract: In general, the present invention provides methods for promoting the function of retinal cells using neuregulins. A novel aspect of the invention involves the use of neuregulins as growth factors tp promote survival of retinal cells. Treating of the retinal cells to provide these effects may be achieved by contacting retinal cells with a polypeptide described herein. The treatments may be provided to slow or halt net cell loss or to increase the amount or quality of retinal tissue present in the vertebrate.
    Type: Grant
    Filed: March 27, 1995
    Date of Patent: June 15, 2004
    Assignee: Acorda Therapeutics
    Inventors: Thomas A. Reh, Mark A. Marchionni, Kathryn L. McCabe, Olivia Bermingham-McDonogh, Nagesh K. Mahanthappa, David I. Gwynne
  • Patent number: 6723748
    Abstract: Disclosed is the use of cloprostenol and fluprostenol analogues in combination with carbonic anhydrase inhibitors for the treatment of glaucoma and ocular hypertension and ophthalmic compositions therefor.
    Type: Grant
    Filed: February 5, 2002
    Date of Patent: April 20, 2004
    Assignee: Alcon Manufacturing, Ltd.
    Inventors: Peter G. Klimko, John E. Bishop, Verney L. Sallee, Paul W. Zinke
  • Patent number: RE39609
    Abstract: The present invention relates to the use of 8-iso prostaglandins and their derivatives for decreasing intraocular pressure, for example in the treatment of glaucoma It is based, at least in part, on the discovery that 8-iso prostaglandin E2 effectively decreased intraocular pressure by a trabecular meshwork outflow mechanism.
    Type: Grant
    Filed: February 11, 2002
    Date of Patent: May 1, 2007
    Assignee: Mount Sinai School of Medicine of New York University
    Inventors: Steven M. Podos, Thomas W. Mittag, Bernard Becker